Clinical Trials Logo

Clinical Trial Summary

A radical cystectomy + extended pelvic lymph node dissection is considered to be the treatment of choice for patients with muscle invasive bladder cancer (MIBC). Despite this aggressive treatment the outcome is poor and ultimately, 30% of the patients with ≥pT3 tumors develop a pelvic recurrence. One- and 2-years survival for patients developing a local recurrence after cystectomy is only 8% and 3% respectively, with a median survival of <4 months. For patients with lymph node recurrence prognosis is somewhat better, but nevertheless still disappointing with reported 1- and 2 years survival of 42% and 11% respectively. The investigators hypothesize that an earlier implementation of external beam radiotherapy (EBRT) i.e. in the adjuvant setting, will prevent local and lymph node recurrence and improve disease free- and overall survival as local recurrence is linked to the development of distant metastasis. Adjuvant EBRT was tested in a prospective randomized trial and resulted in a 20% increase in 5-year disease free survival. Despite those impressive results, severe intestinal toxicity rates hampered the enthusiasm to use adjuvant EBRT, till now. In the last decade, great technological advancements in EBRT planning, such as intensity modulated arc therapy (IMAT), and positioning have been realised. This has resulted in a better coverage of the target volume while sparing normal tissue (mainly small bowel) and in a more precise delivery of the EBRT. Therefore, it is desirable to reconsider the use of adjuvant EBRT in selected MIBC patients.


Clinical Trial Description

The investigators plan to perform a prospective phase 2 study including 76 patients. Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to 64 Gy to the positive lymph nodes will be delivered. Pathological evaluation on cystectomy specimen includes: tumor stage and grade, area of necrosis (absolute and relative), micro vessel density, epidermal growth factor receptor. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02397434
Study type Interventional
Source University Hospital, Ghent
Contact
Status Active, not recruiting
Phase N/A
Start date October 1, 2014
Completion date October 30, 2028

See also
  Status Clinical Trial Phase
Completed NCT02273713 - The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION) Phase 1/Phase 2
Terminated NCT00531076 - Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer Phase 1
Withdrawn NCT03342300 - Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Phase 2/Phase 3
Active, not recruiting NCT02649491 - Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy N/A
Active, not recruiting NCT03975452 - Volume De-escalation in Neoadjuvant Radiochemotherapy of Rectal Cancer N/A
Terminated NCT00618917 - MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Not yet recruiting NCT02760823 - Alpha Lipoic Acid as an Adjuvant Treatment in Acute Phosphide Poisoning Phase 2
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT00890448 - Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate N/A
Terminated NCT01760356 - Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients
Recruiting NCT06044623 - Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients Phase 3
Completed NCT01091766 - Sensitivity of ECG on Detection of Three Different Intravascular Applied Test Doses of Bupivacaine and Epinephrine Phase 4
Completed NCT05277480 - Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) Phase 2
Recruiting NCT03978949 - Prevention of Radiotherapy Induced Enteropathy by Probiotics (PREP) Phase 3
Completed NCT03491371 - Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use N/A
Completed NCT02143219 - Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer Phase 2
Completed NCT02054741 - Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer N/A
Not yet recruiting NCT06087718 - Feasibility of the Maastro Applicator in Rectal Cancer N/A
Terminated NCT02512809 - Isoflurane-induced Neuroinflammation in Children With Hydrocephalus Phase 3
Completed NCT03612544 - The ESTxENDS Trial- Substudy on the Effect on Toxins From Using Electronic Nicotine Delivery Systems (ENDS/Vaporizer/E-cig) N/A